Breast Cancer Clinical Trials in Milan
39 recruitingMilan, Italy
Showing 1–20 of 39 trials
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Breast CancerLung Cancer
Bristol-Myers Squibb416 enrolled63 locationsNCT06618287
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled524 locationsNCT06492616
Recruiting
Phase 1Phase 2
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Breast CancerSolid Tumors, Adult
Eli Lilly and Company720 enrolled67 locationsNCT05768139
Recruiting
Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Breast Cancer
Pfizer1,020 enrolled518 locationsNCT06760637
Recruiting
Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Breast Cancer
AstraZeneca625 enrolled315 locationsNCT06103864
Recruiting
Phase 3
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Breast Cancer
AstraZeneca100 enrolled40 locationsNCT07205822
Recruiting
Phase 1Phase 2
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Breast CancerOvarian CancerEndometrial Cancer+1 more
AstraZeneca460 enrolled67 locationsNCT05123482
Recruiting
Phase 3
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Breast Cancer
Daiichi Sankyo250 enrolled86 locationsNCT05950945
Recruiting
Phase 3
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Breast Cancer
Celcuity Inc674 enrolled203 locationsNCT06757634
Recruiting
Evaluation of See.d as an Automated Blood Sample Preparator for Multiple Liquid Biopsy Applications
Breast CancerHealthy Participants
Tethis S.p.A.45 enrolled1 locationNCT06097156
Recruiting
Phase 2
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
Breast Cancer
BicycleTx Limited66 enrolled39 locationsNCT06840483
Recruiting
Phase 1Phase 2
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Breast CancerMetastatic Breast Cancer
Stemline Therapeutics, Inc.435 enrolled118 locationsNCT05563220
Recruiting
Percutaneous Cryoablation of Low-risk Early Breast Cancer
Breast Cancer
European Institute of Oncology234 enrolled1 locationNCT06300125
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Breast Cancer
Pfizer400 enrolled153 locationsNCT07062965
Recruiting
Not Applicable
Single-fraction APBI for Early-stage Breast Cancer With Favorable Histological Subtypes (Breast-1F)
Breast Cancer
IRCCS San Raffaele311 enrolled1 locationNCT06946238
Recruiting
Phase 3
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Breast Cancer
Greenwich LifeSciences, Inc.750 enrolled161 locationsNCT05232916
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Phase 1
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
Breast CancerAdvanced CancerAdvanced Solid Tumors+1 more
OnKure, Inc.200 enrolled34 locationsNCT06239467
Recruiting
Not Applicable
OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)
Breast CancerProstate CancerNSCLC
European Organisation for Research and Treatment of Cancer - EORTC302 enrolled15 locationsNCT06462963
Recruiting
Not Applicable
5 fr Ultrahypofractionated WBI and SIB for Breast Cancer With Unfavorable Characteristics
Breast Cancer
IRCCS San Raffaele458 enrolled1 locationNCT07020780